Cytodyn Inc (CYDY)

[justdafactss]

Prime example. One minute and 59 seconds after press release 8K filing of hold lifted----

Regulation FD Disclosure.

On August 22, 2023, Fulcrum Therapeutics, Inc., or Fulcrum, issued a press release announcing that the U.S. Food and Drug Administration lifted the clinical hold on the Investigational New Drug application for FTX-6058 for the potential treatment of sickle-cell disease. In connection therewith, Fulcrum posted a program update presentation, or the Presentation, that provides more information about the amended protocol and planned Phase 1b trial of FTX-6058 on the Investor Relations section of its website at www.fulcrumtx.com. A copy of the Presentation entitled “FTX-6058 for Sickle Cell Disease Program Update” is furnished as Exhibit 99.1 hereto and incorporated by reference herein. Fulcrum expressly disclaims any obligation to update the Presentation, or any other information posted on or available through its website, and cautions that the information set forth therein is only accurate as of the date indicated on such materials. The inclusion of any data or statements in the Presentation (or available on or through Fulcrum’s website) does not signify that such information is considered material.
Filing Date
2023-08-22
Accepted
2023-08-22 07:01:59
https://www.sec.gov/Archives/edgar/data/1680581/000119312523217439/0001193125-23-217439-index.htm

FDA Lifts Clinical Hold on Fulcrum Therapeutics’ FTX-6058 for Sickle Cell Disease
August 22, 2023 at 7:00 AM EDT
https://ir.fulcrumtx.com/news-releases/news-release-details/fda-lifts-clinical-hold-fulcrum-therapeutics-ftx-6058-sickle